225Ac-FAPI-XT

N/A

Report date: 2025/11/25 17:50:11

NME

Base Information

Drug Name225Ac-FAPI-XT

Drug Alias NameXT117

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[4]

Mechanisms of ActionFibroblast activation protein alpha binders

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesCancer Hospital of Shandong First Medical University

China Registration ClassN/A

Develop Information

Active CompaniesCancer Hospital of Shandong First Medical University

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A